Skip to main content
. Author manuscript; available in PMC: 2018 May 6.
Published in final edited form as: Curr Treat Options Oncol. 2017 Aug 24;18(10):59. doi: 10.1007/s11864-017-0504-y

Table 1.

Immune checkpoint drugs and associated targets

Drug name Immune checkpoint target
Ipilimumab CTLA-4
Tremelimumab CTLA-4
Pembrolizumab PD-1
Nivolumab PD-1
Avelumab PD-L1
Durvalumab PD-L1
Atezolizumab PD-L1

CTLA-4 cytotoxic T lymphocyte-associated antigen 4, PD-1 programmed cell death 1, PD-L1 programmed cell death ligand 1